These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 29388338)

  • 1. Are physicians neglecting the risk of heart failure in diabetic patients who are receiving sulfonylureas? Lessons from the TOSCA.IT trial.
    Packer M
    Eur J Heart Fail; 2018 Jan; 20(1):49-51. PubMed ID: 29388338
    [No Abstract]   [Full Text] [Related]  

  • 2. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure.
    Arturi F; Succurro E; Miceli S; Cloro C; Ruffo M; Maio R; Perticone M; Sesti G; Perticone F
    Endocrine; 2017 Sep; 57(3):464-473. PubMed ID: 27830456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An observational study goes where randomized clinical trials have not.
    Frakt AB
    JAMA; 2015 Mar; 313(11):1091-2. PubMed ID: 25781429
    [No Abstract]   [Full Text] [Related]  

  • 4. Potential impact of sulfonylureas in the outcome of type 2 diabetic patients with ischemic stroke.
    Arboix A
    Stroke; 2007 Sep; 38(9):2413-4. PubMed ID: 17673799
    [No Abstract]   [Full Text] [Related]  

  • 5. Possible risk of sulfonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease.
    Mühlhauser I; Sawicki PT; Berger M
    Diabetologia; 1997 Dec; 40(12):1492-3. PubMed ID: 9447960
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.
    Vaccaro O; Masulli M; Bonora E; Del Prato S; Giorda CB; Maggioni AP; Mocarelli P; Nicolucci A; Rivellese AA; Squatrito S; Riccardi G;
    Nutr Metab Cardiovasc Dis; 2012 Nov; 22(11):997-1006. PubMed ID: 23063367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrovascular Safety of Sulfonylureas: The Role of KATP Channels in Neuroprotection and the Risk of Stroke in Patients With Type 2 Diabetes.
    Liu R; Wang H; Xu B; Chen W; Turlova E; Dong N; Sun CL; Lu Y; Fu H; Shi R; Barszczyk A; Yang D; Jin T; Mannucci E; Feng ZP; Sun HS
    Diabetes; 2016 Sep; 65(9):2795-809. PubMed ID: 27207539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulfonylureas and mortality in diabetic patients after myocardial infarction.
    Brady PA; Al-Suwaidi J; Kopecky SL; Terzic A
    Circulation; 1998 Feb; 97(7):709-10. PubMed ID: 9495313
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiovascular safety of sulfonylureas: a meta-analysis of randomized clinical trials.
    Monami M; Genovese S; Mannucci E
    Diabetes Obes Metab; 2013 Oct; 15(10):938-53. PubMed ID: 23594109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late complications of diabetes mellitus: risk factors in patients on sulfonylureas for more than 10 years.
    Hoshi M; Fujita S
    Jpn J Med; 1991; 30(6):616-7. PubMed ID: 1798228
    [No Abstract]   [Full Text] [Related]  

  • 12. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
    Acta Diabetol; 2009 Jun; 46(2):145-54. PubMed ID: 19194648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newer Sulfonylureas Not Associated with Increased Mortality, MIs, or Strokes.
    Barry HC
    Am Fam Physician; 2016 Sep; 94(5):386. PubMed ID: 27583428
    [No Abstract]   [Full Text] [Related]  

  • 14. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
    Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: A nationwide study.
    Lee YC; Chang CH; Dong YH; Lin JW; Wu LC; Hwang JS; Chuang LM
    Int J Cardiol; 2017 Feb; 228():1007-1014. PubMed ID: 27923207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The place of sulfonylureas in the therapy for type 2 diabetes mellitus.
    Del Prato S; Pulizzi N
    Metabolism; 2006 May; 55(5 Suppl 1):S20-7. PubMed ID: 16631807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns and determinants of new first-line antihyperglycaemic drug use in patients with type 2 diabetes mellitus.
    Geier AS; Wellmann I; Wellmann J; Kajüter H; Heidinger O; Hempel G; Hense HW
    Diabetes Res Clin Pract; 2014 Oct; 106(1):73-80. PubMed ID: 25139631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis.
    Tang H; Li G; Zhao Y; Wang F; Gower EW; Shi L; Wang T
    Diabetes Obes Metab; 2018 May; 20(5):1262-1279. PubMed ID: 29369494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical effects of levosimendan are not attenuated by sulfonylureas.
    Kivikko M; Nieminen MS; Pollesello P; Pohjanjousi P; Colucci WS; Teerlink JR; Mebazaa A
    Scand Cardiovasc J; 2012 Dec; 46(6):330-8. PubMed ID: 22928945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Standl E; Schnell O
    Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.